ETF Holdings Breakdown of TEVA

Stock Name	Teva Pharma Industries Ltd ADR
Ticker	TEVA(USD) NYSE
TYPE	Common Stock
Country	USA
ISIN	US8816242098
LEI	549300BAFGM4RC74ZJ94

TEVA institutional holdings

The following institutional investment holdings of TEVA have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share
2025-12-11	IE0001YGXFO5 (iShares MSCI World Climate Transition Aware UCITS ETF USD (Acc))	174	USD 5,251	30.18
2025-12-11	IE0009QS7W62 (iShares MSCI World Health Care Sector ESG UCITS ETF USD (Acc))	23,854	USD 719,914	30.18
2025-12-11	IE000OHHIBC6 (iShares Core MSCI World UCITS ETF USD (Dist))	1,670,864	USD 50,426,676 1.3%	30.18
2025-12-11	IE000YNE6S57 (iShares MSCI World Climate Transition Aware UCITS ETF USD (Dist))	174	USD 5,251	30.18
2025-12-11	IE00B0M62Q58 (iShares MSCI World UCITS ETF USD (Dist))	110,125	USD 3,323,573	30.18
2025-12-11	IE00B42YS929 (iShares MSCI World GBP Hedged UCITS ETF (Acc))	8,124	USD 182,495 0.4%	22.46
2025-12-11	IE00B4L5Y983 (iShares Core MSCI World UCITS ETF USD (Acc))	1,670,864	USD 50,426,676	30.18
2025-12-11	IE00B6R52259 (iShares MSCI ACWI UCITS ETF)	292,165	USD 8,817,540 1.3%	30.18
2025-12-11	IE00BD45YS76 (iShares Core MSCI World UCITS ETF GBP Hedged (Dist))	1,670,864	USD 50,426,676	30.18
2025-12-11	IE00BFNM3J75 (iShares MSCI World ESG Screened UCITS ETF)	91,983	USD 2,776,047	30.18
2025-12-11	IE00BFNM3K80 (iShares MSCI World ESG Screened UCITS ETF USD (Dist))	91,983	USD 2,776,047	30.18
2025-12-11	IE00BFYTYS33 (iShares Edge MSCI World Value Factor UCITS USD Dist)	427,139	USD 12,891,055	30.18
2025-12-11	IE00BG11HV38 (iShares MSCI World ESG Enhanced UCITS ETF USD Inc GBP)	12,094	USD 364,997 1.3%	30.18
2025-12-11	IE00BHZPJ569 (iShares MSCI World ESG Enhanced UCITS ETF USD Acc GBP)	12,094	USD 364,997 1.3%	30.18
2025-12-11	IE00BJ5JNZ06 (iShares MSCI World Health Care Sector ESG UCITS ETF)	23,854	USD 719,914	30.18
2025-12-11	IE00BKBF6H24 (iShares Core MSCI World UCITS ETF)	1,670,864	USD 50,426,676	30.18
2025-12-11	IE00BP3QZB59 (iShares Edge MSCI World Value Factor UCITS ETF)	427,139	USD 12,891,055	30.18
2025-12-11	IE00BP3QZD73 (iShares MSCI World Mid-Cap Equal Weight UCITS ETF USD (Acc))	18,527	USD 559,145	30.18
2025-12-10	IE00B441G979 (iShares MSCI World EUR Hedged UCITS ETF (Acc))	70,688 0.3%	USD 1,809,399 5.1%	25.60
2025-12-09	IE00019GPKX6 (iShares MSCI ACWI UCITS ETF SGD Hedged (Acc))	292,165	USD 8,344,232 0.8%	28.56
Total =	8,585,738	USD 258,257,616

News associated with TEVA

HEFA, EFA, TEVA, MNDY: Large Outflows Detected at ETF: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Currency Hedged MSCI EAFE ETF (Symbol: HEFA) where we have detected an approximate $98.6 million dollar outflow -- that's a 1.5% decrease we - 2025-09-19 11:50:18
Noteworthy ETF Inflows: IDEV, CYBR, TEVA, CCEP: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core MSCI International Developed Markets ETF (Symbol: IDEV) where we have detected an approximate $366.0 million dollar inflow -- that's a 1 - 2025-09-08 12:03:35
Notable ETF Inflow Detected - IXUS, AER, TEVA, FUTU: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core MSCI Total International Stock ETF (Symbol: IXUS) where we have detected an approximate $129.6 million dollar inflow -- that's a 0.3% in - 2025-08-25 13:46:54
US Bancorp DE Has $166,000 Stock Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA): US Bancorp DE lifted its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report) by 6.5% in the first quarter, HoldingsChannel reports. The firm owned 10,812 shares of the company’s stock after purchasing an additional 656 shares during the period. US Bancorp DE’s holdings in Teva Pharmaceutical Industries were worth $166,000 at the end […] - 2025-08-17 05:46:51
Deutsche Bank AG Increases Stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA): Deutsche Bank AG grew its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report) by 16.9% in the 1st quarter, HoldingsChannel reports. The firm owned 2,589,607 shares of the company’s stock after buying an additional 375,064 shares during the quarter. Deutsche Bank AG’s holdings in Teva Pharmaceutical Industries were worth $39,802,000 as of its […] - 2025-08-13 05:18:59
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives $24.71 Consensus PT from Analysts: Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Get Free Report) has received a consensus rating of “Buy” from the eight research firms that are covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price […] - 2025-08-04 02:43:01
Wall Street Zen Upgrades Teva Pharmaceutical Industries (NYSE:TEVA) to Buy: Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday. TEVA has been the subject of a number of other reports. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a “neutral” rating […] - 2025-07-28 04:02:50
Signaturefd LLC Trims Stock Holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA): Signaturefd LLC decreased its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report) by 28.8% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,768 shares of the company’s stock after selling 2,739 shares during the period. Signaturefd LLC’s holdings in […] - 2025-07-22 07:20:51
Head to Head Comparison: Teva Pharmaceutical Industries (NYSE:TEVA) vs. Taysha Gene Therapies (NASDAQ:TSHA): Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) and Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings. Profitability This table compares Taysha Gene […] - 2025-07-22 02:45:38
Bank of New York Mellon Corp Sells 11,648 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA): Bank of New York Mellon Corp lessened its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report) by 0.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,609,696 shares of the company’s stock after selling 11,648 shares during […] - 2025-07-17 04:32:51
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Sold by Envestnet Asset Management Inc.: Envestnet Asset Management Inc. trimmed its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report) by 5.7% during the first quarter, HoldingsChannel reports. The firm owned 1,921,762 shares of the company’s stock after selling 116,779 shares during the period. Envestnet Asset Management Inc.’s holdings in Teva Pharmaceutical Industries were worth $29,537,000 at the end […] - 2025-07-15 05:14:50
DekaBank Deutsche Girozentrale Decreases Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA): DekaBank Deutsche Girozentrale decreased its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report) by 2.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 72,127 shares of the company’s stock after selling 1,453 shares during the period. DekaBank Deutsche Girozentrale’s […] - 2025-07-14 05:34:47
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives $24.13 Consensus Price Target from Analysts: Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Get Free Report) have earned a consensus rating of “Buy” from the nine analysts that are presently covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average […] - 2025-07-10 02:50:52
GAMMA Investing LLC Sells 3,068 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA): GAMMA Investing LLC trimmed its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report) by 41.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,390 shares of the company’s stock after selling 3,068 shares during the […] - 2025-07-09 04:24:51
Teva Pharmaceutical Industries Sees Unusually Large Options Volume (NYSE:TEVA): Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Get Free Report) saw some unusual options trading activity on Monday. Stock investors purchased 59,369 put options on the stock. This is an increase of approximately 93% compared to the typical volume of 30,826 put options. Teva Pharmaceutical Industries Stock Down 1.0% TEVA stock opened at $16.84 on Tuesday. […] - 2025-07-08 02:20:24
Retirement Systems of Alabama Makes New Investment in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA): Retirement Systems of Alabama acquired a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 401,249 shares of the company’s stock, valued at approximately $6,167,000. Other large investors […] - 2025-06-25 05:08:59
IXUS, TEVA, TME, MNDY: ETF Inflow Alert: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core MSCI Total International Stock ETF (Symbol: IXUS) where we have detected an approximate $593.1 million dollar inflow -- that's a 1.3% in - 2025-06-20 12:07:30
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Holdings Reduced by QRG Capital Management Inc.: QRG Capital Management Inc. lessened its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report) by 12.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 129,430 shares of the company’s stock after selling 18,708 shares during […] - 2025-06-20 05:38:53
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Given Consensus Recommendation of “Buy” by Brokerages: Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Free Report) has been given a consensus rating of “Buy” by the ten brokerages that are presently covering the company, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average […] - 2025-06-12 05:30:57
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Sees Large Increase in Short Interest: Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Free Report) was the recipient of a significant increase in short interest in the month of May. As of May 15th, there was short interest totalling 38,700,000 shares, an increase of 36.1% from the April 30th total of 28,430,000 shares. Based on an average trading volume of 12,300,000 […] - 2025-06-04 05:04:50
B. Riley Wealth Advisors Inc. Buys New Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA): B. Riley Wealth Advisors Inc. bought a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 9,689 shares of the company’s stock, valued at approximately $214,000. Other hedge funds and other institutional […] - 2025-06-02 05:40:56
Teva Pharmaceutical Industries (NYSE:TEVA) Now Covered by Truist Financial: Truist Financial assumed coverage on shares of Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) in a report issued on Wednesday, MarketBeat.com reports. The brokerage issued a buy rating and a $25.00 price target on the stock. TEVA has been the topic of several other reports. Barclays reduced their price target on Teva Pharmaceutical Industries from […] - 2025-05-29 03:14:53
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives Consensus Recommendation of “Buy” from Analysts: Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Free Report) has earned a consensus rating of “Buy” from the eight analysts that are presently covering the stock, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price […] - 2025-05-23 06:58:47
Captrust Financial Advisors Has $182,000 Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA): Captrust Financial Advisors decreased its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 47.6% during the 4th quarter, HoldingsChannel reports. The fund owned 8,279 shares of the company’s stock after selling 7,507 shares during the quarter. Captrust Financial Advisors’ holdings in Teva Pharmaceutical Industries were worth $182,000 as of its most recent […] - 2025-05-23 04:47:03
Traders Purchase High Volume of Call Options on Teva Pharmaceutical Industries (NYSE:TEVA): Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Free Report) saw unusually large options trading activity on Wednesday. Stock investors acquired 170,268 call options on the company. This is an increase of 417% compared to the average daily volume of 32,957 call options. Institutional Investors Weigh In On Teva Pharmaceutical Industries A number of hedge funds […] - 2025-05-23 02:22:47
Focus Partners Wealth Has $845,000 Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA): Focus Partners Wealth lifted its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 8.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 38,335 shares of the company’s stock after purchasing an additional 3,071 […] - 2025-05-19 05:16:57
Teva Pharmaceutical Industries (NYSE:TEVA) Stock Rating Upgraded by JPMorgan Chase & Co.: Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) was upgraded by JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a report released on Monday, MarketBeat reports. The brokerage presently has a $23.00 target price on the stock, up from their previous target price of $21.00. JPMorgan Chase & Co.‘s target […] - 2025-05-14 04:30:54
First Trust Advisors LP Sells 58,194 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA): First Trust Advisors LP lowered its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 66.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 29,818 shares of the company’s stock after selling 58,194 shares during the quarter. First Trust Advisors LP’s holdings […] - 2025-05-09 05:04:48
Teva Pharma Boosts FY25 Adj. EPS Outlook - Update: (RTTNews) - While reporting financial results for the first quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) raised its adjusted earnings guidance for the full-year 2025, while trimming annual revenue outlook. - 2025-05-07 08:40:47
Pre-Market Most Active for May 5, 2025 : TSLL, SQQQ, TQQQ, PLTR, NVDA, WOLF, IBIT, HIMS, TEVA, NIO, WELL, QBTS: The NASDAQ 100 Pre-Market Indicator is down -203.41 to 19,899.2. The total Pre-Market volume is currently 69,701,327 shares traded.The following are the most active stocks for the pre-market session: Direxion Daily TSLA Bull 2X Shares (TSLL) is -0.1602 at $10.41, with 9,379,797 - 2025-05-05 09:29:53

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.